Results 171 to 180 of about 1,736,515 (318)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Application of Laser-Induced Breakdown Spectroscopy (LIBS) technology in malignant tumor diagnosis. [PDF]

Discov Oncol
Chen J, Luo P, Wang S, Yang H.
europepmc   +1 more source

[MALIGNANT TUMORS OF THE PROSTATE].

Showa Igakkai zasshi = The Journal of the Showa Medical Association, 1963
Akasaka, Hiroshi, Iijima, Hiroshi, Maruyama, Yukitaka   +2 more
openaire   +2 more sources

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Prognostic Factors and Risk Stratification in Malignant Tumor Patients With Sepsis: A Retrospective Cohort Study. [PDF]

Med Sci Monit
Wang Y, Liu H, Chen Y, Shen Y.
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Letter: The risk-benefit balance of CRISPR-Cas screening systems in gene editing and targeted cancer therapy

Journal of Translational Medicine
Qiang Yi, Xinting Ouyang, Gangfeng Zhu, Jinghua Zhong   +3 more
doaj   +1 more source

Case report: thoracic syphilitic gumma masquerading as a malignant tumor in a patient with AIDS. [PDF]

AIDS Res Ther
Luo J, Guo W, Zou S, Tan Y, Liu J, Song S, Yang H, Liang K.   +7 more
europepmc   +1 more source

From tumor‐centric to ecosystem‐based hypotheses in brain tumor research and care

Molecular Oncology, EarlyView.
Primary brain tumors, whether in adults or children, present a major challenge because of their dramatic prognosis and the ongoing lack of efficient therapeutic approaches. In recent years, a shift has occurred from tumor‐centric concepts to a more holistic view of these tumors as dynamic ecosystems.
Julie Gavard, Flavie Bénard, Eva Billat, Margaux Le Guyon, Victoria Maltret, Laura Merlet, Chloé Astrid Walter, Tony Avril, Eric Chevet   +8 more
wiley   +1 more source

Factors influencing malignant tumor development in cats from a multicenter retrospective study. [PDF]

Sci Rep
Fonti N, Carnio A, Cocumelli C, Dhein ES, Eleni C, Galietta V, Guscetti F, Lachi A, Parisi F, Poli A, Scaramozzino P, Millanta F.   +11 more
europepmc   +1 more source